Michelle Rosenzwajg
University of Paris
Publications 96
Introduction Actuellement, les inhibiteurs de check-points immunitaires (ICI) sont recommandes pour le traitement de plus de 16 types de cancers differents et le nombre de patients eligibles ne cesse d’augmenter notamment avec l’approbation recente dans le cancer du sein. La gestion des toxicites immunitaires induites par ces anticorps monoclonaux anti-cytotoxic-T-lymphocyte-associated protein-4 (CTLA4) ou anti-programme cell death 1/programme cell death ligand 1 (PD1/PDL1) devient cruciale. En ...
#1Cloé ComarmondH-Index: 18
#2Valérie Lorin (French Institute of Health and Medical Research)H-Index: 8
Last.David Saadoun (University of Paris)H-Index: 20
view all 16 authors...
Abstract Background & Aims Hepatitis C virus (HCV) infection contributes to the development of autoimmune disorders such as cryoglobulinemia vasculitis (CV). However, it remains unclear why only some HCV-infected individuals develop CV. HCV-CV is characterized by expansions of anergic CD19 + CD27 + CD21 low/- atypical memory B cells (AtM). Here, we report the mechanisms by which AtM participate to HCV-associated autoimmunity. Methods Phenotype and function of peripheral AtM were studied by multi...
#1Sebastien Halter (University of Paris)
#2Lucrèce Aimade (University of Paris)
Last.Antoine Monsel (University of Paris)H-Index: 18
view all 9 authors...
Abstract Backgrounds Acute respiratory distress syndrome (ARDS) is a common and fatal inflammatory condition. Whether T regulatory cells (Tregs) are beneficial or detrimental remains controversial, and longitudinal studies are lacking. Phenotyping of Tregs activation markers has been poorly reported. We aimed to evaluate quantitative and functional alterations in blood and bronchoalveolar Treg phenotype of ARDS patients. Methods We performed a single-centre observational study in a French intens...
Objective Regulatory T cells (Tregs) prevent autoimmunity and control inflammation. Consequently, any autoimmune or inflammatory disease reveals a Treg insufficiency. As low-dose interleukin-2 (ld-IL2) expands and activates Tregs, it has a broad therapeutic potential. Aim We aimed to assess this potential and select diseases for further clinical development by cross-investigating the effects of ld-IL2 in a single clinical trial treating patients with 1 of 11 autoimmune diseases. Methods We perfo...
22 CitationsSource
#1Guillaume Churlaud (University of Paris)H-Index: 8
#2Chadi Abbara (University of Angers)H-Index: 4
Last.David Klatzmann (University of Paris)H-Index: 63
view all 9 authors...
2 CitationsSource
#1Fabien Pitoiset (University of Paris)H-Index: 8
#2Michèle Barbié (University of Paris)H-Index: 1
Last.Michelle Rosenzwajg (University of Paris)H-Index: 29
view all 10 authors...
Background: Quantification of regulatory T cells (Tregs) is crucial in immunomonitoring in clinical trials as this cell population has been shown to be involved in a wide range of diseases, including cancers, auto-immune diseases, infections, and allergies. Human Tregs are defined as CD4 1 CD25 1 CD127 low FoxP3 1 cells, and the standardization of their staining by flow cytometry is a challenge, especially in multicenter clinical trials, notably because of the intracellular location of FoxP3. Me...
12 CitationsSource
#1Guillaume Churlaud (University of Paris)H-Index: 8
#2Michelle Rosenzwajg (University of Paris)H-Index: 29
Last.David Klatzmann (University of Paris)H-Index: 63
view all 8 authors...
1 CitationsSource
#1Roberta LorenzonH-Index: 3
#2Encarnita Mariotti-Ferrandiz (University of Paris)H-Index: 5
Last.David KlatzmannH-Index: 63
view all 29 authors...
Introduction Autoimmune and autoinflammatory diseases (AIDs) represent a socioeconomic burden as the second cause of chronic illness in Western countries. In this context, the TRANSIMMUNOM clinical protocol is designed to revisit the nosology of AIDs by combining basic, clinical and information sciences. Based on classical and systems biology analyses, it aims to uncover important phenotypes that cut across diagnostic groups so as to discover biomarkers and identify novel therapeutic targets. Me...
1 CitationsSource
#1Fabien Pitoiset (University of Paris)H-Index: 8
#2L. Cassard (French Institute of Health and Medical Research)H-Index: 4
Last.Michelle Rosenzwajg (University of Paris)H-Index: 29
view all 9 authors...
5 CitationsSource
#1Roberta Lorenzon (University of Paris)H-Index: 3
#2Iannis Drakos (University of Paris)H-Index: 1
Last.Encarnita Mariotti-Ferrandiz (University of Paris)H-Index: 5
view all 25 authors...
Objectives: Autoimmune and inflammatory diseases (AIDs) form a continuum of autoimmune and inflammatory diseases, yet AIDs' nosology is based on syndromic classification. The TRANSIMMUNOM trial (NCT02466217) was designed to re-evaluate AIDs nosology through clinic-biological and multi-omics investigations of patients with one of 19 selected AIDs. To allow cross-analyses of clinic-biological data together with omics data, we needed to integrate clinical data in a harmonized database. Materials an...